Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DIRECTION: Discontinuation versus continuation of riociguat after successful BPA in CTEPH
2026-525351-81-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of riociguat in chronic thromboembolic pulmonary hypertension (CTEPH) (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Clinical worsening at longest follow-up. Planned start Aug 2026; status: authorised.
02
Drugs
riociguat
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on 2026-525351-81-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525351-81-00.